Cargando…
An analysis of orphan medicine expenditure in Europe: is it sustainable?
BACKGROUND: Orphan medicinal product (OMP) prices are considered by some to be a challenge to the sustainability of healthcare expenditure. These concerns are compounded by the increasing number of OMPs receiving marketing authorisation (MA) annually. The aim of this study was to explore the sustain...
Autores principales: | Mestre-Ferrandiz, Jorge, Palaska, Christina, Kelly, Tom, Hutchings, Adam, Parnaby, Adam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907352/ https://www.ncbi.nlm.nih.gov/pubmed/31829218 http://dx.doi.org/10.1186/s13023-019-1246-7 |
Ejemplares similares
-
Comparing access to orphan medicinal products in Europe
por: Zamora, Bernarda, et al.
Publicado: (2019) -
Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates
por: Espin, Jaime, et al.
Publicado: (2018) -
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020
por: Schey, Carina, et al.
Publicado: (2011) -
Principles for consistent value assessment and sustainable funding of orphan drugs in Europe
por: Gutierrez, Laura, et al.
Publicado: (2015) -
New pricing models for generic medicines to ensure long-term sustainable competition in Europe
por: Francois, Clement, et al.
Publicado: (2023)